Navigation Links
Synutra International, Inc. Amends August 2005 Current Report on Form 8-K and Annual Report on Form 10-K for the Fiscal Year Ended March 31, 2007
Date:1/15/2008

QINGDAO, China and ROCKVILLE, Md., Jan. 15 /Xinhua-PRNewswire/ -- Synutra International, Inc. (Nasdaq: SYUT; ''Synutra''), one of China's leading manufacturers of dairy-based nutritional products for infants, children and adults, today filed amendments to its Current Report on Form 8-K filed on August 22, 2005 and its Annual Report on Form 10-K for the fiscal year ended March 31, 2007 with the U.S. Securities and Exchange Commission. As explained in the Forms 8-K and 10-K, the amendments are the result of certain deficiencies and errors in Synutra's financial statements identified during its ongoing assessment process to improve the effectiveness of its disclosure controls and procedures and internal control over financial reporting.

Synutra previously concluded that the audited consolidated Balance Sheets, Income Statements and Cash Flow Statements as of and for the calendar years ended December 31, 2003 and 2004 and unaudited consolidated Balance Sheets, Income Statements and Cash Flow Statements as of and for the three and six months ended June 30, 2004 and 2005 of its wholly owned subsidiary, Synutra Inc. (''Synutra Illinois''), should no longer be relied upon because of errors in such financial statements. The Current Report on Form 8-K filed today restates Synutra Illinois' financial statements to (i) reclassify certain other income as sales revenue and (ii) breakout certain cash and cash equivalents into cash and restricted cash line items.

Synutra also previously concluded that certain filings made subsequent to the Form 8-K filed on August 22, 2005, including Synutra's Annual Report on Form 10-K for the fiscal year ended March 31, 2007 and Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended March 31, 2007, which presented audited financial statements covering the 12-month periods ended March 31, 2005, 2006, and 2007 (together, the ''Form 10-K"), should have presented, but did not present, audited financial statements for the three- month transition period ended March 31, 2005, unaudited comparative financial statements for the three months ended March 31, 2004 and audited financial statements for the 12-month period ended December 31, 2004 rather than audited financial statements for the 12-month period ended March 31, 2005. Synutra has amended its Form 10-K to present such periods and provide related disclosures to the Management's Discussion and Analysis and other items of the Form 10-K.

During the assessment of its disclosure controls and procedures and internal control over financial reporting, Synutra also analyzed its financial position, changes in financial position and results of operations as of the same dates and for the same periods for which audited consolidated financial statements have been presented, and determined that the restricted net assets of Synutra's consolidated subsidiaries not available for distribution to Synutra as of March 31, 2007 exceeded certain thresholds. Synutra has amended its Form 10-K to include Schedule I to present its condensed financial information for the years ended March 31, 2006 and 2007 as part of the financial statements as required by Articles 12-04(a) and 4-08(e)(3) of Regulation S-X. Synutra also has added disclosure to the notes to the financial statements of the Form 10-K to describe its assessment of the restricted net assets of its consolidated subsidiaries. Finally, Synutra identified an error in the Cash Flow Statements for the year ended March 31, 2006 in which the depreciation expense amount was misstated. Synutra has revised the data column for the year ended March 31, 2006 in the Cash Flow Statements to reflect the correct depreciation amount of that period.

Synutra International, Inc. Chairman and Chief Executive Officer Liang Zhang commented, ''We continually strive to improve our financial reporting and to have the utmost transparency in our communications. I believe that the team that we have in place is a strong one, and I am confident that we have improved, and will continue to improve, both our financial reporting and our internal controls over such reporting. Synutra remains focused on capturing the growth in the infant formula industry in China through successful strategic execution, and I am optimistic about our prospects as we enter 2008.''

Synutra's SEC filings are available on-line: http://www.synutra.com

About Synutra International, Inc.

Synutra operates eight subsidiaries developing, producing, distributing and selling dairy-based nutritional products across the People's Republic of China. It offers its products for infants, children, adults and pregnant women and nursing mothers under the brand series of ''Super,'' ''U-Smart" and "U- Strong.'' The Group's extensive sales network covers 24 provinces, 264 cities and more than 1320 counties throughout China. For more information, please contact Weiguo Zhang of Synutra, Inc. (301 840 3888, wzhang@synutra.com), Brian Rafferty of Taylor Rafferty (212 889 4350, synutra@taylor-rafferty.com) or visit: http://www.synutra.com .

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

For more information, please contact:

Mr. Weiguo Zhang

Synutra, Inc.

Tel: +1-301-840-3888

Email: wzhang@synutra.com

Mr. Brian Rafferty

Taylor Rafferty

Tel: +1-212-889-4350

Email: synutra@taylor-rafferty.com


'/>"/>
SOURCE Synutra International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nasdaq Informs Synutra that the Companys Filing Delinquency has been Cured
2. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
3. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
4. Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
5. Cryo-Cell International, Inc. Reports Third Quarter 2007 Results
6. TenderCare International, Inc. Announces Signing of Merger Agreement with the Hain Celestial Group for All Outstanding Shares of TenderCare Stock
7. Chindex International, Inc. Announces Results for the Quarter and Six Months Ended September 30, 2007
8. DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results
9. Chindex International, Inc. Announces Transfer to NASDAQ Global Market
10. MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP
11. Z Trim Holdings Reports Restatement of Previously Issued Financial Statements; Amends Bylaws
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: